1. Home
  2. BLTE vs OBDE Comparison

BLTE vs OBDE Comparison

Compare BLTE & OBDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLTE
  • OBDE
  • Stock Information
  • Founded
  • BLTE 2018
  • OBDE 2020
  • Country
  • BLTE United States
  • OBDE United States
  • Employees
  • BLTE N/A
  • OBDE N/A
  • Industry
  • BLTE Biotechnology: Pharmaceutical Preparations
  • OBDE
  • Sector
  • BLTE Health Care
  • OBDE
  • Exchange
  • BLTE Nasdaq
  • OBDE NYSE
  • Market Cap
  • BLTE 2.1B
  • OBDE 1.9B
  • IPO Year
  • BLTE 2022
  • OBDE N/A
  • Fundamental
  • Price
  • BLTE $64.12
  • OBDE $15.02
  • Analyst Decision
  • BLTE Strong Buy
  • OBDE Buy
  • Analyst Count
  • BLTE 4
  • OBDE 1
  • Target Price
  • BLTE $89.00
  • OBDE $16.00
  • AVG Volume (30 Days)
  • BLTE 62.6K
  • OBDE 448.1K
  • Earning Date
  • BLTE 11-12-2024
  • OBDE 02-08-2025
  • Dividend Yield
  • BLTE N/A
  • OBDE 3.92%
  • EPS Growth
  • BLTE N/A
  • OBDE N/A
  • EPS
  • BLTE N/A
  • OBDE N/A
  • Revenue
  • BLTE N/A
  • OBDE N/A
  • Revenue This Year
  • BLTE N/A
  • OBDE N/A
  • Revenue Next Year
  • BLTE N/A
  • OBDE N/A
  • P/E Ratio
  • BLTE N/A
  • OBDE N/A
  • Revenue Growth
  • BLTE N/A
  • OBDE N/A
  • 52 Week Low
  • BLTE $31.01
  • OBDE $13.60
  • 52 Week High
  • BLTE $86.53
  • OBDE $16.80
  • Technical
  • Relative Strength Index (RSI)
  • BLTE 44.50
  • OBDE 60.14
  • Support Level
  • BLTE $60.00
  • OBDE $14.66
  • Resistance Level
  • BLTE $76.87
  • OBDE $15.03
  • Average True Range (ATR)
  • BLTE 4.51
  • OBDE 0.18
  • MACD
  • BLTE -0.44
  • OBDE -0.01
  • Stochastic Oscillator
  • BLTE 24.42
  • OBDE 50.00

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

About OBDE BLUE OWL CAPITAL CORP III

Blue Owl Capital Corp III is focused on originating and making loans to, and debt and equity investments in middle-market companies based predominantly in the United States. Its objective is to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns. The company invests in senior secured or unsecured loans, subordinated loans or mezzanine loans and, to a lesser extent, equity and equity-related securities including warrants, preferred stock and similar forms of senior equity, which may or may not be convertible into a portfolio company's common equity.

Share on Social Networks: